OSWG s Role in Shaping the Regulatory Development of Oligos - A Potential Model for Moving Forward -
|
|
- Gary Lindsey
- 6 years ago
- Views:
Transcription
1 OSWG s Role in Shaping the Regulatory Development of Oligos - A Potential Model for Moving Forward - David H. Schubert VP, Regulatory and Quality
2 Outline What? Background and History Who? How? OSWG Committees and Publications Is the OSWG Valuable? Slide 2
3 The OSWG Oligo Safety Working Group A group of industry and regulatory professionals who choose to engage in addressing the nonclinical safety issues and challenges associated with the development of oligonucleotide-based therapeutics - Open forum where scientific & regulatory principles are discussed - Slide 3
4 Background Mid 2000s. Shift from the development of oligonucleotides as a academic interest to an active industry New class of pharmaceutical compound faced regulatory challenges that perhaps might not be best served by the current rules for small molecules or biological products Slide 4
5 Background (cont.) Oligonucleotide-based therapy IND and Pre-IND submissions (n=105) were on the increase. 16 Number of INDs and PreINDs Year S. Leigh Verbois, DIA Oligo Mtg, OSWG, 14June2010 Slide 5
6 Background (cont.) Rise in new ON classes of drugs being developed Oligonucleotide IND and Pre-INDs submissions by decade and class PS-ASO 2'-MOE CpG Aptamer sirna Miscellaneous S. Leigh Verbois, DIA Oligo Mtg, OSWG, 14June2010 Slide 6
7 Background (cont.) Nonclinical Safety Regulatory Assessments Genetic Toxicology? Exaggerated Pharmacology Immunomodulatory Off-Target Effects Diverse Mechanisms of Action Repro & Developmental Tox Slide 7
8 History In st DIA (Drug Information Association) Oligonucleotide-based Therapeutics Conference Douglas Throckmorton s closing remarks challenged Sponsors and Regulators to work together OSWG formally established January 2008 Slide 8
9 Objectives To share information, facilitate dialog and enable discussion on issues (observed and anticipated) in the development of synthetic oligonucleotides as drugs Reflect current thinking of members, companies and regulatory authorities on issues Goal Provide recommendations on the best practice for nonclinical development of oligonucleotides-based therapeutics Slide 9
10 Membership Includes representatives from >30 pharmaceutical companies (US, EU and Japan) >10 independent consultants Regulatory agencies (FDA, Health Canada, EU) Started as Yahoo group Joined DIA, a neutral community, March 2013 Group in Biotechnology & Innovative Preclinical Sciences Community Access group need to be DIA member Participation open to all interested parties Slide 10
11 Structure Hold monthly teleconference meetings Last Tuesday at 12 noon, EST (1 hour) Subcommittee updates Forum for open communication Way for new members to connect with Subcommittees Subcommittees Meet routinely Define issues within the area Develop goals/charter for the subgroup Develop/affect change in those areas Strive to share info and/or data to support the issues Slide 11
12 Subcommittees Genotox Exaggerated Pharmacology - retired Immunomodulatory Inhalation- retired Repro & Carci Safety Pharmacology Formulated Oligos - new Publications Slide 12
13 Accomplishments Organized and participated in 6 DIA specific Oligonucleotide-based Therapeutics Conferences to date Next September 2015 Generated 7 peer reviewed publications In process of generating additional white papers Successfully justified exclusion of synthetic oligonucleotides from definition of Advanced Medicinal Products (e.g. gene therapy) as proposed by the European Commission 2009/ Actively involved in responses to NIH proposal requiring RAC review of clinical protocols for synthetic oligonucleotides Slide 13
14 Genotox Objective: Provide guidance on evaluation of genotoxic potential for an oligo-drugs that considers the platform issues A primary question is the appropriateness of standard genotoxicity tests established primarily for small molecules Ames Assay (bacterial gene mutation) Mouse Lymphoma Assay (Mammalian Cell Mutation test) Chromosome Aberration Test Micronucleus Test (i.e., mouse) What tests are appropriate and when they are appropriate have been proposed to regulatory agencies FDA has not established a formal position 2005 reflection paper by EMEA White Paper is written and out for external review Slide 14
15 Exaggerated Pharmacology (EP) Adverse effects resulting from the intended pharmacology Excludes off-target effects and non-specific (class) effects Relevance to clinical development is dependent on multiple factors Know or perceived clinical impact Primary and secondary effects Magnitude and duration of the effect Slide 15
16 EP (cont.) Evaluation has varied over time and among regulatory agencies Reflection of the progression from viral targets, to cancer targets, to targets involved in normal cell processes Knowledge base throughout the industry has increased and thus consistency among companies and regulatory agencies This topic has received considerable debate among OSWG participants and in the ON community EP Subcommittee published consensus document in 2013 Slide 16
17 EP Publication Kornbrust D, et al. (2013) Oligo safety working group exaggerated pharmacology subcommittee consensus document. Nucleic Acid Ther. Feb;23(1):21-8. doi: /nat Epub 2013 Jan 4. Slide 17
18 EP (cont.) Subcommittee recommendations: Case-by-case considerations about MOA, structure, nature of target, duration of effect, tissue persistence, route/exposure, duration of treatment, clinical indication, etc. Class differences for oligonucleotides can influence if and how the evaluation can be conducted mirna - Aptamers -Immunostimulatory Identification of relevant species for toxicology evaluation is desirable, but in the absence of activity in multiple species, assessment in one species may be sufficient If no cross-species activity, the use of animal active analogues should be considered The use of analogues posses challenges to the development program, resource-intensive and increases risk for misleading results Slide 18
19 Immunomodulatory Complement activation Summary of experience in non-human primates following exposure to phosphorothioate containing oligonucleotides Status: Summary document completed. White Paper in progress Immunomodulatory effects Comparison between those designed for Toll like receptor mediation from those designed to function through non-immune MOA Status: Summary document ongoing via dialogue on monthly TCons Risk assessment of immunomodulation: Induction of autoimmune responses? Activation of local immune system versus systemic: proliferation and redistribution of immune cells Selection of biomarkers for risk assessment Status: some discussion included in above TCons Slide 19
20 Inhalation To date, the number of non-clinical and clinical studies for inhalation of ON are limited and additional data is needed Subcommittee identified key questions/issues for consideration Response of the lung to ON Type (single strand, duplex, length) and chemical modifications (conjugates) Response of the lung to formulations Species differences; rodent vs. NHP, NHP vs. human Exposure differences Models/biomarkers to monitor lung toxicity and relevance to humans (species, assays, endpoints) Subcommittee published consensus points and recommendations in 2012 Slide 20
21 Inhalation Publication Alton EW, et al. (2012) Clinical Expert Panel on Monitoring Potential Lung Toxicity of Inhaled Oligonucleotides: Consensus Points and Recommendations Nucleic Acid Ther.; 22(4) : doi: /nat Slide 21
22 Safety Pharmacology ICH S7A does not specifically call out oligonucleotides; similar to other guidelines this should be applied as appropriate. investigate the potential undesirable pharmacodynamic effects of a substance on physiological functions in relation to exposure in the therapeutic range and above. Appropriateness of dedicated safety pharmacology studies should be determined by the data and indication If the toxicology studies do not provide a clear answer this may need a specific study focused on a organ system Clinical indication/route of administration may require dedicated safety pharmacology studies Safety Pharm Subcommittee published consensus document in 2014 Slide 22
23 Safety Pharm Publication Berman C, et al. (2014) Recommendations for Safety Pharmacology Evaluations of Oligonucleotide-Based Therapeutics. Nucleic Acid Ther. Jun 19. [Epub ahead of print] Slide 23
24 Safety Pharmacology Subcommittee recommendations: Safety pharm testing, as described ICH S7 guidance, is as applicable as it is to small molecule drugs and biotherapeutics Study design considerations Similar to those for other classes of drugs Studies should evaluate the drug product administered via the clinical route Species selection should ideally consider relevance of the model with regard to the endpoints of interest, pharmacological responsiveness, and continuity with the nonclinical development program. Evaluation of potential effects in the core battery (CV, CNS, and Resp) is recommended. In general: In vitro herg testing does not provide any specific value and is not warranted Emphasis on in-vivo evaluation of cardiovascular function, typically in nonhuman primates (NHPs) Due to the low level of concern, neurologic and respiratory function can be assessed concurrently with cardio-vascular safety pharmacology evaluation in NHPs, within repeat-dose toxicity studies, or as stand-alone studies (rodents are most commonly used). Other dedicated safety pharmacology studies, beyond the core battery, may have limited value Slide 24
25 Off-Target Effects The most debated issue among OSWG participants and in oligonucleotide community Always a hot-button for people coming into the field Definition Hybridization-dependent change in the expression of an unintended target; can be upregulation or down-regulation Can be a direct sequence-based effect Can be a secondary effect Change in expression results in a adverse effect Class effects, such as toxicities due to chemistry, or toxicity due to delivery systems are not off-target effects mirna agonists and antagonists are intended to modulate multiple pathways and not all pathways are recognized Off-target may actual be on-target Slide 25
26 Off-Target Effects Points to Consider Significance of an off-target effect is influenced by potential and consequence Confirmation/evaluation by in vitro or in vivo models can provide critical information for assessing off-target effects Pharmacology and toxicology studies conducted in preclinical development provide the most convincing evidence Assumes potential off-target effects can be monitored and appropriate monitoring will be included in studies Species differences should be considered when potential off-target effect is suspected Off-Target Subcommittee published consensus document in 2012 Slide 26
27 OT Publication Lindow M, et al. (2012) Assessing unintended hybridization induced biological effects of oligonucleotides. Nature Biotechnology; 30: doi: /nbt.2376 Slide 27
28 Off-Target Effects Subcommittee recommendations: Off-target effects can occur with all drug classes Oligonucleotides probably do not posses any greater potential for off-target effects maybe less Compared to small molecules it is easier to predict off-target effects for oligos Best Practice approach to the evaluation of off-target effects In silico screening - find sequences with minimized potential for off-target hybridization-dependent effects Characterization should be on a case by case basis Exploration of off-target effects should be data driven and given careful consideration Toxicity studies in two species remain best way to detect unintended effects Slide 28
29 Repro Publication Cavagnaro J, et al. (2014) Considerations for Assessment of Reproductive and Developmental Toxicity of Oligonucleotide-based Therapeutics. Nucleic Acid Ther. DOI: /nat Slide 29
30 Repro & Developmental Tox Subcommittee recommendations: ONs have attributes that are similar to NCEs and NBEs Both sets of guidelines can be useful when planning reproductive toxicity studies; (ICH) S5 (R2)/ ICH S6(R1) Approach to DART should take into account both potential effects of chemical structure & intended pharmacology of the ON Standard reproductive toxicity species (rodent/rabbit) can often be used because most ON toxicity is related to chemical structure Animal-active surrogates can be useful to assess potential reproductive effects related to pharmacology in addition to effects related to the chemical back-bone Slide 30
31 Repro & Developmental Tox Subcommittee recommendations (cont.): Choice of the relevant animal model, the dosing regimen, and whether to use the clinical candidate or an animal surrogate will all need to be considered carefully based on the specific product attributes of the ON Information from general toxicity studies and previous experience with similar ONs can also help to inform these decisions NHP studies should be used only as needed to answer specific questions or when surrogates are not practical Dosing regimens should be tailored to ensure adequate exposure throughout the period of organogenesis without compromising the ability to assess PDand PK-related effects Slide 31
32 Emerging Topics Formulated Oligos Charter being developed Carcinogenicity Designated as an area for OSWG subcommittee focus Appropriateness of carci studies for ONs Clinical dosing schedule and patient population Pharmacology/toxicology profile in target organs Extent and duration of exposure to target organs If carcinogenicity studies are required can this can be accomplished in rodents? Slide 32
33 Is the OSWG Valuable? Industry perspective Allows for establishment of uniform views of important topics across the industry Presenting OSWG work at various scientific meetings provides a collective voice for its members and their work in OSWG. Educates scientists who are new to this field, so that we can move projects forward with a relatively good degree of consistency across programs, at least with regard to some of the key scientific and regulatory strategies. Provides a conduit for passing on our legacy of oligo safety assessment expertise to the next generation of oligo toxicologists White papers and publications represent consensus opinions of the knowledgeable pharmaceutical scientists working in this area and serve as a guide for newcomers and others who may have uncertainties about specific aspects of oligo safety. Slide 33
34 Is the OSWG Valuable? Regulatory Perspective Those of us interested in oligonucleotide therapeutics in the agency recognize that the OSWG provides a useful forum in which companies and others can share information. The agency appreciates the opportunity to hear these discussions and is interested in reading the published accounts of these discussions. OSWG allows regulators to listen to OSWG discussions, affording them an opportunity to hear about the challenges and current thinking from an industry perspective Slide 34
35 OSWG Experience Commitment with meaningful discussions and common understanding helps move the conversations forward.. Slide 35
36 THANK YOU! Slide 36
37 OSWG Publications List Berman C, et al. (2014) Recommendations for Safety Pharmacology Evaluations of Oligonucleotide-Based Therapeutics. Nucleic Acid Ther. Jun 19. [Epub ahead of print] Kornbrust D, et al. (2013) Oligo safety working group exaggerated pharmacology subcommittee consensus document. Nucleic Acid Ther. Feb;23(1):21-8. doi: /nat Epub 2013 Jan 4. Alton EW, et al. (2012) Clinical Expert Panel on Monitoring Potential Lung Toxicity of Inhaled Oligonucleotides: Consensus Points and Recommendations Nucleic Acid Ther.; 22(4) : doi: /nat Schubert D, et al. (2012) The Oligonucleotide Safety Working Group (OSWG). Nucleic Acid Ther. 22(4): doi: /nat Capaldi D, et al. (2012) Quality Aspects of Oligonucleotide Drug Development: Specifications for Active Pharmaceutical Ingredients (API), Therapeutic Innovation & Regulatory Science; doi: / Lindow M, et al. (2012) Assessing unintended hybridization induced biological effects of oligonucleotides. Nature Biotechnology; 30: doi: /nbt Cavagnaro J, et al. (2014) Considerations for Assessment of Reproductive and Developmental Toxicity of Oligonucleotidebased Therapeutics. Nucleic Acid Ther. DOI: /nat Slide 37
ICH S9 guideline on nonclinical evaluation for anticancer pharmaceuticals - questions and answers
16 May 2018 EMA/CHMP/ICH/453684/2016 Committee for Human Medicinal Products ICH S9 guideline on nonclinical evaluation for anticancer pharmaceuticals - questions and answers Step 5 Transmission to CHMP
More informationImpurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA
Overview of exploratory INDs Impurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA July, 15 16, 2008 David Jacobson-Kram, Ph.D. DABT Office of New Drugs Center for Drug Evaluation
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) POSITION PAPER ON NON-CLINICAL SAFETY STUDIES TO SUPPORT CLINICAL TRIALS WITH A SINGLE MICRODOSE
European Medicines Agency Evaluation of Medicines for Human Use London, 23 June 2004 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) POSITION PAPER ON NON-CLINICAL SAFETY STUDIES TO SUPPORT CLINICAL
More informationWhat can be done from regulatory side?
Federal Agency for Medicines and Health Products (FAMHP) What can be done from regulatory side? 9th Annual ecopa Workshop November 29-30, 2008, Brussels Dr. Sonja BEKEN Non-Clinical Assessor, Registration
More informationS9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers
S9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers Current Step 4 version International Council for Harmonisation of Technical
More informationAccelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective
Accelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective Imran M. Khan, Ph.D. Division of Psychiatry Center for Drug Evaluation and Research FDA
More informationPharmacology. Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University.
Pharmacology Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University. 1 PHARMACODYNAMIC STUDIES A. Primary pharmacodynamics primary action in target
More informationInternational Consortium For Innovation & Quality in Pharmaceutical Development
International Consortium For Innovation & Quality in Pharmaceutical Development s on Draft Guidance: FDA Draft Guidance: Investigational Enzyme Replacement Therapy Products: Nonclinical Assessment (draft
More informationComments and suggestions from reviewer
Comments and suggestions from reviewer Page 1 of 13 Title: WHO Guidelines on the Quality, Safety, and Efficacy of Biological Medicinal Products Prepared by Recombinant DNA Technology: WHO/rDNA_DRAFT/12
More informationOncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory Challenges
The content of this presentation reflects the opinion of the speaker and does not necessarily represent the official position of CDER Oncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory
More information06/03/2009. Overview. Preclinical Support for Exploratory Phase I Clinical Trials. Micro-dosing IND. Pharmacological Active Single Dose IND
Preclinical Support for Exploratory Phase I Clinical Trials Clive Joseph, DSRD Sandwich Overview Identify the most appropriate development paradigm - traditional vs alternative IND approach Confidence
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS OF MEDICINAL PRODUCTS
European Medicines Agency London, 24 January 2008 Doc. Ref. EMEA/CHMP/SWP/258498/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS
More informationRe: Docket No. FDA-2009-D-0006 S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org April 20, 2009 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,
More informationGuideline on the non-clinical requirements for radiopharmaceuticals
1 2 3 15 November 2018 EMA/CHMP/SWP/686140/2018 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Draft Draft agreed by Safety Working Party October 2018 Adopted by CHMP for release for consultation
More informationBasic principles of the safety assessment of drugs
Basic principles of the safety assessment of drugs SFT Annual meeting 2013 Björn Dahl, PhD Senior Project Director Global Safety Assessment AstraZeneca R&D Outline of presentation Safety assessment in
More informationDetection of toxicity to reproduction for human pharmaceuticals. Explanatory slides agreed by EWG members
Detection of toxicity to reproduction for human pharmaceuticals Explanatory slides agreed by EWG members 2 October 2017 International Council for Harmonisation of Technical Requirements for Pharmaceuticals
More informationToxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development
Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development No. 1 of 10 1. regulates all the drugs products manufactured and sold in the USA. (A) EMEA (B) IND (C) FDA (D) NDA (E) OSHA
More informationS9 Nonclinical Evaluation for Anticancer Pharmaceuticals
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create
More informationRegulatory compliance in Non-Clinical development
Regulatory compliance in Non-Clinical development SME Workshop Presented by Milton Bonelli on 3 October 2016 Clinical Pharmacology and Non-Clinical Office - Human Medicines R & D Support Division An agency
More informationFirst-in-human clinical trials Behind the scenes
First-in-human clinical trials Behind the scenes Dr Douglas Francis BVSc MVSc PhD, UK/European registered toxicologist Principal Regulatory Toxicologist Prior to review by Bellberry Ethics Committee Identify
More information! Background. ! What is really new?! The new Section 7: Explorative Clinical Trials (ECTs) ! Consequences in General
! Background! What is really new?! The new Section 7: Explorative Clinical Trials (ECTs)! 5 Approaches (Table 3) for:! Microdose trials (7.1)! Single-Dose (SD) Trials at Sub-therapeutic Doses or Into the
More informationPreclinical studies needed in the development of human pharmaceutical drugs role of toxicology and risk assessment
Preclinical studies needed in the development of human pharmaceutical drugs role of toxicology and risk assessment Hubert Dirven Lead Validation Unit - NPI Amersham Health (GE Healthcare), Oslo Preclinical
More informationMicrodose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations Guidance for Industry
Microdose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationS9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers
S9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers Current version dated 8 June 2016 International Council for Harmonisation of
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS OF MEDICINAL PRODUCTS
European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 13 October 2005 Doc. Ref. CHMP/EMEA/CHMP/SWP/258498/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
More informationFDA Public Hearing: Approval Pathway for Biosimilar. Products. November 2-3, 2010
FDA Public Hearing: Approval Pathway for Biosimilar and Interchangeable Biological Products November 2-3, 2010 1 The Biotechnology Industry Organization Over 1,100 members, including biotechnology companies,
More informationFDA Perspective on the Preclinical Evaluation of Biological Therapies for Cancer
FDA Perspective on the Preclinical Evaluation of Biological Therapies for Cancer Yongjie Zhou, M.D., Ph.D. FDA/CBER/OCTGT/DCEPT Yongjie.zhou@fda.hhs.gov isbtc Global Regulatory Summit October 29, 2008
More informationNon-clinical Assessment Requirements
Non-clinical Assessment Requirements Presented by: Maria Nieto-Gutierrez Safety and Efficacy of Medicines/Human Medicines Development and Evaluation An agency of the European Union Contents: Relevance
More informationICH Considerations Oncolytic Viruses ONCOLYTIC VIRUSES (EMEA/CHMP/ICH/607698/2008) TRANSMISSION TO CHMP November 2008
European Medicines Agency October 2009 EMEA/CHMP/ICH/607698/2008 ICH Considerations Oncolytic Viruses ONCOLYTIC VIRUSES (EMEA/CHMP/ICH/607698/2008) TRANSMISSION TO CHMP November 2008 TRANSMISSION TO INTERESTED
More informationStructure and content of an IMPD. What is required for first into man trial?
What is required for first into man? The EU IMPD Thomas Sudhop, MD Scope Structure and content of an IMPD What is required for first into man trial? Only for IMPs that do not have a marketing authorisation
More informationICH CONSIDERATIONS Oncolytic Viruses
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ICH CONSIDERATIONS Oncolytic Viruses 20 November 2008 EMEA/CHMP/GTWP/607698/2008
More informationPreclinical Development of Biologics: Case-by-case, so get off of my case!
Preclinical Development of Biologics: Case-by-case, so get off of my case! Northeast Chapter SOT David Jacobson-Kram, Ph.D., DABT Office of New Drugs Center for Drug Evaluation and Research FDA October
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/42832/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR
More informationLaura Andrews, PhD, DABT, Fellow ATS
Laura Andrews, PhD, DABT, Fellow ATS What is a Biologic? From PHS Act of 1944 A biologic is any virus, toxin, antitoxin, therapeutic serum, vaccine, blood, blood component or derivative, allergenic products
More informationS2(R1) Revision of the Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use
S2(R1) Revision of the Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use Peter Kasper BfArM and S2(R1)EWP International Conference on Harmonisation of
More informationICH Topic S 6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. Step 5
European Medicines Agency March 1998 CPMP/ICH/302/95 ICH Topic S 6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON PRECLINICAL SAFETY EVALUATION OF BIOTECHNOLOGY-DERIVED
More informationOptimisation de votre programme de développement
Optimisation de votre programme de développement Cedric Lamy, PhD. Cedric.lamy@crl.com Charles River Overview 65-year history: Founded in 1946, publicly traded (NYSE:CRL) Investment in skilled staff: ~7,500
More informationFrom Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager
From Discovery to Development of new Drugs. and pitfalls along the way by Kim Dekermendjian, PhD in Medicine BD & Key Account manager The roots of Drug Discovery Before 20 th century the term didn't exists,
More informationICH Considerations. Oncolytic Viruses September 17, 2009
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH Considerations Oncolytic Viruses September 17, 2009 1. Introduction Oncolytic viruses
More informationJuvenile toxicity studies with biopharmaceuticals : considerations and current practices
Juvenile toxicity studies with biopharmaceuticals : considerations and current practices Shaun Maguire Toxicologist, Biologics Safety Assessment, MedImmune, Cambridge, UK maguires@medimmune.com AGAH Workshop
More informationFDA Perspective on the Preclinical Development of Cancer Vaccines
FDA Perspective on the Preclinical Development of Cancer Vaccines Richard D. McFarland Ph.D., M.D. Medical Officer CBER/OCTGT/DCEPT mcfarlandr@cber.fda.gov Cancer Vaccine Clinical Trials Workshop Alexandria,
More informationRe: Docket No. FDA-2015-D-1246: Draft Guidance on Investigational Enzyme Replacement Therapy Products: Nonclinical Assessment
July 13, 2015 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA-2015-D-1246: Draft Guidance on Investigational Enzyme Replacement
More informationKey Aspects of Non-Clinical Pharmacology and Pharmacokinetics in the Evaluation of Safety
Safeguarding public health Key Aspects of Non-Clinical Pharmacology and Pharmacokinetics in the Evaluation of Safety David R Jones (david.jones@mhra.gsi.gov.uk) Expert Pharmacotoxicologist, Medicines and
More informationICH S9 -Nonclinical Evaluation for Anticancer Pharmaceuticals: Questions and Answers
ICH S9 -Nonclinical Evaluation for Anticancer Pharmaceuticals: Questions and Answers May 2018 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 1 Legal
More informationICH 교육가이드라인 [ 안전성 & 품질 ]
ICH 교육가이드라인 [ 안전성 & 품질 ] 1 SAFETY ( 안전성 ) Safety Series / 11 월 27 일 ( 화 ) ICH S9 guideline is focused on anticancer drugs. However, for better understanding, the presentation will give the comparison with
More informationCombining Large Animal IND Enabling Toxicology and CV Sph Studies- PRO
Safety Pharmacology Endpoints: Integration into Toxicology Studies Combining Large Animal IND Enabling Toxicology and CV Sph Studies- PRO Marc Bailie DVM, PhD Director In Vivo Facility Michigan State University,
More informationSUBMISSION OF COMMENTS ON The Requirements for First-in-Human Clinical Trials for Potential High Risk Medicinal Products EMEA/CHMP/SWP/28367/2007
European Medicines Agency SUBMISSION OF COMMENTS ON The Requirements for First-in-Human Clinical Trials for Potential High Risk Medicinal Products EMEA/CHMP/SWP/28367/2007 COMMENTS FROM The Biotechnology
More informationPRECLINICAL DRUG DISCOVERY AND DEVELOPMENT BIOBOOT CAMP 2016
PRECLINICAL DRUG DISCOVERY AND DEVELOPMENT BIOBOOT CAMP 2016 1 FROM DISCOVERY TO COMMERCIALIZATION At least 10 years on average Average spend of $1.4B Less than 12% of drugs entering Phase I are approved
More informationInvestigational New Drug Application
Investigational New Drug Application Regulatory Sponsor: Funding Sponsor: Study Product: Protocol Number: Name of the Sponsor-Investigator Department Name Address Phone Number Name of Primary Funding Institution
More informationRevidierte ICH M3 Auswirkungen auf die präklinische Arzneimittelentwicklung. Pharmakologie, ADME, Missbrauchs- Potential und Kombinations-Toxizität
Revidierte ICH M3 Auswirkungen auf die präklinische Arzneimittelentwicklung Pharmakologie, ADME, Missbrauchs- Potential und Kombinations-Toxizität PD Dr. Elke Röhrdanz Präklinik Fachgebiet Klinische Prüfung
More informationNonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies. Whitney S. Helms, PhD IOM, February 29,2016
Nonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies Whitney S. Helms, PhD IOM, February 29,2016 Disclaimer The views disseminated in this talk are my own and do not necessarily represent
More informationIMPURITIES IN NEW DRUG PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Recommended for
More informationSPEED UP YOUR TIME TO MARKET
SPEED UP YOUR TIME TO MARKET #Pre-clinical #Biologics #Small molecules Welcome to Accelera. As a Contract Research Organization (CRO) serving since more than 30 years pharmaceutical and biotechnology companies
More informationExploratory clinical trials workshop
Exploratory clinical trials workshop Yves Donazzolo, Grenoble / Lyon Dominique Tremblay, Paris AGAH / Club Phase I meeting Lyon, April 28 & 29, 2009 Topics Introduction Definitions Nonclinical safety studies
More informationA Life-cycle Approach to Dose Finding Studies
A Life-cycle Approach to Dose Finding Studies Rajeshwari Sridhara, Ph.D. Director, Division of Biometrics V Center for Drug Evaluation and Research, USFDA This presentation reflects the views of the author
More informationMAINTENANCE OF THE ICH GUIDELINE ON NON-CLINICAL SAFETY STUDIES FOR THE CONDUCT OF HUMAN CLINICAL TRIALS FOR PHARMACEUTICALS M3(R1)
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE MAINTENANCE OF THE ICH GUIDELINE ON NON-CLINICAL
More informationConducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development
Conducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development 2015 AAPS Annual Meeting and Exposition October 28, 2015 Kimberly Raines, Ph.D. Lead Pharmacologist Quality
More informationScientific Considerations in Demonstrating Biosimilarity to a Reference Product. Guidance for Industry
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationRegulatory Issues and Drug Product Approval for Biopharmaceuticals
Regulatory Issues and Drug Product Approval for Biopharmaceuticals Vinod P. Shah, Ph. D. FIP Scientific Secretary Biotech 2007 Southern African Regional and International Regulatory Biotechnology Workshop
More informationTransmission to CHMP July Adoption by CHMP for release for consultation 20 July Start of consultation 31 August 2017
1 2 3 29 August 2017 EMA/CHMP/ICH/544278/1998 Committee for Human Medicinal Products 4 ICH S5 (R3) guideline on reproductive toxicology: 5 detection of toxicity to reproduction for human 6 pharmaceuticals
More informationAdding Safety Pharm Endopoints To General Tox Studies - II
Adding Safety Pharm Endopoints To General Tox Studies - II Michael J Engwall, DVM, PhD Principal Scientist Safety and Exploratory Pharmacology Toxicology Sciences Amgen, Inc. Should Safety Pharmacology
More informationDr. S. Harinarayana Rao
Dr. S. Harinarayana Rao Theatre, Indian Habitat Centre, New Delhi July 30 31, 2013 Introduction Classification ICH 6 guidelines Innovative methods RCGM and EMEA Challenges Conclusion What is a biopharmaceutical
More informationNon-clinical documentation Overview of Requirements
3 rd EMEA-. Non-clinical Aspects Non-clinical documentation Overview of Requirements EMEA Pre-Authorisation Human Unit 3 rd EMEA-. Non-clinical Aspects Outline Overview of Legal and Regulatory requirements
More informationDocket #: FDA-2018-D-3268
Subject: Comment on FDA Draft Guidance for Industry Titled Rare Diseases: Early Drug Development and the Role of Pre-Investigational New Drug Application Meetings Docket #: FDA-2018-D-3268 ARM is an international
More informationEngage with us on Twitter: #Molecule2Miracle
Engage with us on Twitter: #Molecule2Miracle Kassy Perry President & CEO Perry Communications Group PhRMA Alliance Development Consultant.@kassyperry Emily Burke, Ph.D. Director of Curriculum BioTech
More informationFDA Regulation of Companion Diagnostics
FDA Regulation of Companion Diagnostics Paul Radensky October 11, 2017 Disclosure + Slideset drawn from Part I of presentation made by Janice Hogan, HoganLovells, October 2016 + Updated where appropriate
More informationPIP s Pup s and Problems
PIP s Pup s and Problems Graham Bailey, Senior Scientific Director and Fellow Reproductive and Juvenile Toxicology Drug Safety Sciences Janssen Pharmaceutica N.V Pediatric Medicine Until ~10 years ago,
More informationComparative Study of Regulatory Requirements for Biologics Filing in United States and European Union
Comparative Study of Regulatory Requirements for Biologics Filing in United States and European Union Mr. Shashi Kumar Yadav Assistant Professor Sri Indu Institute of Pharmacy Hyderabad Outline Introduction
More informationfact sheet 3 Introduction to Biosimilars & Regulatory Requirements
3 fact sheet 3 Introduction to Biosimilars & Regulatory Requirements International Alliance of Patients Organizations CAN Mezzanine 49-51 East Road London N1 6AH United Kingdom International Federation
More informationAgreed with W. Cornell Graduate Program and Tri-I
Drug Development Course From Molecule to Prescription Weill Cornell Graduate School - Tri-Institutional Therapeutics Discovery Institute ABOUT THIS COURSE This course has been designed in collaboration
More informationInternational Council for Harmonisation (ICH) Safety Guideline Updates
International Council for Harmonisation (ICH) Safety Guideline Updates ICH Regional Public Meeting Canada-U.S. Regulatory Cooperation Council November 12, 2015 Alisa Vespa, Ph.D. Health Canada Active ICH
More informationInternational Transfers of Personal Data at sanofi-aventis R & D
International Transfers of Personal Data at sanofi-aventis R & D Pierre-Yves Lastic, PhD Senior Director, Standards Management & Data Privacy Sanofi-aventis R&D CONFERENCE ON INTERNATIONAL TRANSFERS OF
More informationHow Targets Are Chosen. Chris Wayman 12 th April 2012
How Targets Are Chosen Chris Wayman 12 th April 2012 A few questions How many ideas does it take to make a medicine? 10 20 20-50 50-100 A few questions How long does it take to bring a product from bench
More informationHarmonizing clinical trials for Biogenerics. Dr. Akhilesh Sharma M.D.;C Clin. Research & P.V. (UCBC - USA & Luton - UK)
Harmonizing clinical trials for Biogenerics Dr. Akhilesh Sharma M.D.;C Clin. Research & P.V. (UCBC - USA & Luton - UK) Senior Vice President & Global Head Global Medical Affairs (C.M.O) Dr. Reddy's Laboratories
More informationCombination Drug Applications: Nonclinical Reviewer Perspectives. Jessica J. Hawes, Ph.D.
Combination Drug Applications: Nonclinical Reviewer Perspectives Jessica J. Hawes, Ph.D. Disclaimer The opinions expressed in this presentation are solely my own and do not reflect those of the FDA, nor
More informationICH Topic M 3 (R2) Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals.
European Medicines Agency June 2009 CPMP/ICH/286/95 ICH Topic M 3 (R2) Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals Step 4 NOTE FOR
More informationGuidance for Industry
Reprinted from FDA s website by Guidance for Industry Scientific Considerations in Demonstrating Biosimilarity to a Reference Product DRAFT GUIDANCE This guidance document is being distributed for comment
More informationPaving the way for Non-Clinical Bioanalytical Partnerships Louise Angell
Paving the way for Non-Clinical Bioanalytical Partnerships Louise Angell Content Overview of non-clinical immunogenicity testing for biologics Regulatory guidance Bioanalytical considerations Risk based
More informationNIH-RAID: A ROADMAP Program
NIH-RAID: A ROADMAP Program (Rapid Access to Interventional Development} A Program designed to facilitate the development of new therapeutics The NIH-RAID Pilot Program is intended to reduce some of the
More informationGuideline for the Quality, Safety, and Efficacy Assurance of Follow-on Biologics
Provisional Translation (as of April 19, 2013) PFSB/ELD Notification No. 0304007 March 4, 2009 To: Prefectural Health Department (Bureau) From: Evaluation and Licensing Division, Pharmaceutical and Food
More informationACG Public Forum. Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD. Monday, 12:45 pm 2:15 pm
ACG Public Forum Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD Monday, 12:45 pm 2:15 pm Overview of the Regulatory Pathway and FDA s Guidance for the Development and Approval of Biosimilar
More informationFrom Drug Discovery to IND Saving Time and Money Through Smart Study Design
From Drug Discovery to IND Saving Time and Money Through Smart Study Design Stephen Madden BSc PhD CBiol FSB Head, Metabolism and Pharmacokinetics Charles River Preclinical Services, Edinburgh Outline
More informationExpectations for Biodistribution (BD) Assessments for Gene Therapy (GT) Products
Expectations for Biodistribution (BD) Assessments for Gene Therapy (GT) Products Approved by the IPRP Management Committee on 3 June 2018 12 April 2018 Table of Contents 1. Position Statement... 3 2. Executive
More informationImplications for Preclinical and Clinical Programs. Novartis Pharmaceuticals Oncology Business Unit June 2, 2011
EU Biosimilarityi il it Guidance Implications for Preclinical and Clinical Programs Shefali Kakar Novartis Pharmaceuticals Oncology Business Unit June 2, 2011 Biologics are more complex than small molecules
More informationCOMMISSION DIRECTIVE 2009/120/EC
15.9.2009 Official Journal of the European Union L 242/3 DIRECTIVES COMMISSION DIRECTIVE 2009/120/EC of 14 September 2009 amending Directive 2001/83/EC of the European Parliament and of the Council on
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 1 2 3 London, 23 July 2009 EMEA/CHMP/BMWP/301636/2008 4 5 6 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT
More informationPreclinical safety testing of diagnostic and therapeutic radiopharmaceuticals - regulatory requirements
ESSR 14: 17th European Symposium on Radiopharmacy and Radiopharmaceuticals Pamplona, 25 April 2014 Preclinical safety testing of diagnostic and therapeutic radiopharmaceuticals - regulatory requirements
More informationInstitute of Pharmaceutical Technology and Biopharmacy University of Pécs szeptember 22. 1
Institute of Pharmaceutical Technology and Biopharmacy University of Pécs 2017. szeptember 22. 1 Pre-discovery Goal: Understand the disease and choose a target molecule. How: Scientists in pharmaceutical
More informationParacelsus Course Objectives: Toxicology for the Laboratory Animal Scientist. General Toxicology Investigations. Reproductive Toxicology
Toxicology for the Laboratory Animal Scientist CL Davis Foundation Topics in Laboratory Animal Medicine May 7, 2009 Angela King-Herbert, DVM, DACLAM NTP/NIEHS RTP NC Course Objectives: Define terms used
More informationPre Pre-IND and Pre-IND Interactions for Cell and Gene Therapy Products
Pre Pre-IND and Pre-IND Interactions for Cell and Gene Therapy Products Theresa Chen, PhD Division of Clinical Evaluation and Pharmacology/Toxicology (DCEPT) Office of Tissues and Advanced Therapies (OTAT)
More informationToxicity Testing for Oncology Drugs Theresa Reynolds, Krishna Allamneni
Toxicity Testing for Oncology Drugs Theresa Reynolds BA, DABT Director, Toxicology Genentech, Inc. Krishna Allamneni DVM, PhD, DABT Scientist, Toxicology Genentech, Inc. 1 This presentation represents
More informationUNLEASH THE POWER OF PRECISION MEDICINE
FROM BENCH TO BEDSIDE UNLEASH THE POWER OF PRECISION MEDICINE DCB, pioneer in biotech. Your partner in drug discovery. www.dcb.org.tw The Center for Biotechnology With over 400 dedicated researchers and
More informationCOMMITTEE FOR THE MEDICINAL PRODUCT FOR HUMAN USE (CHMP)
European Medicines Agency London, 26 April 2007 Doc. Ref. EMEA/CHMP/GTWP/367513/2006 COMMITTEE FOR THE MEDICINAL PRODUCT FOR HUMAN USE (CHMP) CONCEPT PAPER ON The development of a Guideline on clinical
More informationDevelopment of a new medicinal product. as. MUDr. Martin Votava, PhD.
Development of a new medicinal product as. MUDr. Martin Votava, PhD. Development and registration of a medicinal product Costs of development: 800 mil USD Time to develop: 10 years Successfulness: 0,005%
More informationICH Topic Q 3 B Impurities in New Medicinal Products
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit ICH Topic Q 3 B Impurities in New Medicinal Products Step 4, Consensus Guideline, 6 November 1996 TE FOR GUIDANCE
More informationGuideline for the quality, safety and efficacy of follow-on biological medicinal products
Guideline for the quality, safety and efficacy of follow-on biological medicinal products 1. Introduction A follow-on biological medicinal product (hereinafter referred to as FOBMP) is considered as a
More informationNSE Grantees Meeting December 2015
NSE Grantees Meeting December 2015 The Spherical Nucleic Acid (SNA) Nanoparticle Changes the Paradigm for Oligo Therapeutics Linear DNA SNA Each company limited by chemistry, modality, and tissue of interest
More informationRegulatory Perspective
Regulatory Perspective Presented by Dr Maria Isaac MASc, MD, PhD, Pharmaceutical Medicine Physician, Psychiatrist Senior Scientific Officer An agency of the European Union Disclaimer The views expressed
More informationM7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk
M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk This draft guidance, when finalized, will represent the Food and Drug Administration's
More informationRecommendation on elements required to support the medical plausibility and the assumption of significant benefit for an orphan designation
2 March 2010 EMA/COMP/15893/2009 Final Committee for Orphan Medicinal Products (COMP) Recommendation on elements required to support the medical plausibility and the assumption of significant benefit for
More information